Table 1 Primary diagnosis and prior anti-cancer treatment
Number (%) of patients | Mogamulizumab 1 mg/kg + Utomilumab, by Dose Group | ||||
|---|---|---|---|---|---|
1.2 mg/kg n = 11 | 100 mg n = 6 | 2.4 mg/kg n = 4 | 5 mg/kg n = 3 | Total n = 24 | |
CRC | 1 | 0 | 1 | 0 | 2 |
NSCLC | 2 | 6 | 1 | 1 | 10 |
Ovarian Cancer | 0 | 0 | 0 | 1 | 1 |
SCCHN | 8 | 0 | 2 | 1 | 11 |
Prior anti-cancer drug regimens | |||||
 1 | 1 (9.1) | 0 | 1 (25.0) | 0 | 2 (8.3) |
 2 | 3 (27.3) | 3 (50.0) | 0 | 0 | 6 (25.0) |
 3 | 2 (18.2) | 2 (33.3) | 1 (25.0) | 3 (100.0) | 8 (33.3) |
  ≥ 4 | 5 (45.5) | 1 (16.7) | 2 (50.0) | 0 | 8 (33.3) |